Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001172661-25-001264
Filing Date
2025-02-14
Accepted
2025-02-14 17:18:53
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 9004
  Complete submission text file 0001172661-25-001264.txt   10711
Mailing Address 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 650-624-1100
RIGEL PHARMACEUTICALS INC (Subject) CIK: 0001034842 (see all company filings)

EIN.: 943248524 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-59985 | Film No.: 25630982
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 510 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10022
Business Address 510 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10022 (212) 231-4932
ARMISTICE CAPITAL, LLC (Filed by) CIK: 0001601086 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A